Last $106.89 USD
Change Today +0.96 / 0.91%
Volume 11.0M
As of 2:24 PM 09/19/14 All times are local (Market data is delayed by at least 15 minutes).
text size: T | T
Back to Snapshot
Company Description

Contact Info

333 Lakeside Drive

Foster City, CA 94404

United States

Phone: 650-574-3000

Fax: 650-578-9264

Gilead Sciences, Inc., a research-based biopharmaceutical company, is engaged in the discovery, development, and commercialization of medicines in areas of unmet medical need. The company has operations in North and South America, Europe and Asia-Pacific. The company’s primary areas of focus include human immunodeficiency virus (HIV), liver diseases such as chronic hepatitis B virus (HBV) infection and chronic hepatitis C virus (HCV) infection, oncology/inflammation and serious cardiovascular and respiratory conditions. In the liver diseases area, the company received approval from the U.S. Food and Drug Administration (FDA) of new drug application (NDA) for Sovaldi (sofosbuvir 400 mg). Sovaldi is a once-daily oral nucleotide analog polymerase inhibitor for the treatment of HCV infection as a component of a combination antiviral treatment regimen. The company also received approval of Tybost (cobicistat) and Vitekta (elvitegravir 85 mg and 150 mg), each a component of Stribild, from the European Commission. In the oncology/inflammation area, the company filed for FDA and European Medicines Agency (EMA) marketing approval of idelalisib (formerly GS-1101), an investigational, targeted, oral inhibitor of PI3K delta, for the treatment of patients with refractory indolent non-Hodgkin’s lymphoma (iNHL) and relapsed chronic lymphocytic leukemia (CLL). The company also continued to advanced research and development pipeline, with approximately 200 active clinical studies in 2013, of which approximately 60 were in Phase 3 clinical trials. Products HIV Stribild is an oral formulation dosed once a day for the treatment of HIV-1 infection in treatment-naive adults. Stribild is a third complete single regimen for the treatment of HIV and is a fixed-dose combination of antiretroviral medications, Vitekta, Tybost, Viread and Emtriva (emtricitabine). Stribild was approved by the FDA in August 2012 and the European Medicines Agency (EMA) in May 2013. Complera/Eviplera is an oral formulation dosed once a day for the treatment of HIV-1 infection in adults. The product, marketed in the United States as Complera and in Europe as Eviplera, is the second complete single tablet regimen for the treatment of HIV and is a fixed-dose combination of antiretroviral medications, Viread and Emtriva, and Janssen R&D Ireland (Janssen)’s non-nucleoside reverse transcriptase inhibitor, Edurant (rilpivirine). Atripla is an oral formulation dosed once a day for the treatment of HIV infection in adults. It is a fixed-dose combination of antiretroviral medications, Viread and Emtriva and Bristol Myers-Squibb Company's (BMS) non-nucleoside reverse transcriptase inhibitor, Sustiva (efavirenz). Truvada (emtricitabine and tenofovir disoproxil fumarate) is an oral formulation dosed once a day as part of combination therapy to treat HIV infection in adults. It is a fixed-dose combination of antiretroviral medications, Viread and Emtriva. Viread is an oral formulation of a nucleotide analog reverse transcriptase inhibitor, dosed once a day as part of combination therapy to treat HIV infection in patients two years of age and older. Viread is also approved for the treatment of chronic HBV in adults. Emtriva is an oral formulation of a nucleoside analog reverse transcriptase inhibitor, dosed once a day as part of combination therapy to treat HIV infection in adults. In the United States and Europe, Emtriva is also available as an oral solution approved as part of combination therapy to treat HIV infection in children. Tybost is a pharmacokinetic enhancer dosed once a day that boosts blood levels of certain HIV medicines. Tybost is indicated as a boosting agent for the HIV protease inhibitors atazanavir and darunavir as part of antiretroviral combination therapy in adults with HIV-1 infection. The company received marketing approval of Tybost in all 28 countries of the European Union. Vitekta is an oral formulation of an integrase inhibitor, dosed once a day as part of combination therapy to treat HIV infection in adults without known mutations associated with resistance to elvitegravir, the active ingredient of Vitekta. The compa

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
GILD:US $106.89 USD +0.96

GILD Competitors

Market data is delayed at least 15 minutes.

Company Last Change
AbbVie Inc $59.26 USD -0.1901
Amgen Inc $143.73 USD +1.71
AstraZeneca PLC 4,579 GBp +42.00
Bristol-Myers Squibb Co $51.59 USD +0.47
Eli Lilly & Co $66.58 USD -0.01
View Industry Companies
 

Industry Analysis

GILD

Industry Average

Valuation GILD Industry Range
Price/Earnings 23.5x
Price/Sales 9.1x
Price/Book 9.8x
Price/Cash Flow 21.0x
TEV/Sales 7.9x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact GILEAD SCIENCES INC, please visit www.gilead.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.